Application of Shexiang Baoxin Pill Combined with Rosuvastatin Calcium Tablets in the Treatment of Angina Pectoris due to Coronary Atherosclerotic Heart Disease

Objective: To analyze the therapeutic efficacy of Shexiang Baoxin Pill combined with Rosuvastatin Calcium Tablets (ROS) in patients with angina pectoris due to coronary atherosclerotic heart disease (CHD-AP). Methods: Eighty CHD-AP patients admitted for treatment from January 2023 to December 2024 were selected and evenly divided using a random number table. The combined group (40 cases) received treatment with Shexiang Baoxin Pill combined with ROS, while the reference group (40 cases) received ROS monotherapy. The overall response rate, frequency and duration of AP attacks, blood lipid levels, and cardiac function indicators were compared between the two groups. Results: The combined group exhibited a higher overall response rate than the reference group. After treatment, the frequency and duration of AP attacks were lower in the combined group than in the reference group. Additionally, blood lipid levels and cardiac function indicators were superior in the combined group (p < 0.05). Conclusion: The combination of Shexiang Baoxin Pill and ROS demonstrates favorable therapeutic effects in CHD-AP patients, effectively preventing AP attacks, regulating blood lipid levels, protecting cardiac function, and reducing disease risk.